QX 013N
Alternative Names: QX-013NLatest Information Update: 24 Feb 2023
At a glance
- Originator Qyuns Therapeutics
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Urticaria
Most Recent Events
- 14 Feb 2023 Preclinical trials in Urticaria in China (Parenteral) (Qyuns Therapeutics pipeline, February 2023)